Patents Examined by Kagnew H. Gebreyesus
  • Patent number: 11208631
    Abstract: A composition including two exogenous enzymes from animals for consumption by human being before and/or after consuming alcohol to prevent, treat and/or alleviate veisalgia and/or symptoms associated therewith arising from or caused by excessive consumption of alcohol through a dual-enzyme based breakdown of the excess alcohol is provided, wherein a first enzyme of the two exogenous enzymes is capable of converting alcohol into a first metabolite while a second enzyme thereof is capable of converting the first metabolite into a second metabolite which is excretable to systemic circulation after an oxidation reaction of the alcohol in the presence of the two exogenous enzymes and NAD+/NADH; the first enzyme to the second enzyme is in a molar ratio that maintains a ratio between the first and second metabolites in the human being so as to avoid local elevation of the first metabolite in the human being after consumption of excess alcohol.
    Type: Grant
    Filed: May 5, 2021
    Date of Patent: December 28, 2021
    Assignee: ALCOLEAR LIMITED
    Inventors: Bing Lou Wong, Sek Lun Law
  • Patent number: 11203773
    Abstract: Engineered 23S rRNAs and methods of use thereof for translation of proteins incorporating non-standard amino acids are provided. Typically, the 23S rRNA includes one or more mutations at positions 2496-2507 relative to E. coli wildtype 23S rRNA, wherein a ribosome composed of the 23S rRNA can catalyze the covalent transfer of a non-standard amino acid from an aminoacyl-RNA onto a nascent peptide chain. For example, the 23S rRNA can include the sequence UGACUU at positions 2502-2507 relative to E. coli wildtype 23S rRNA, and optionally the sequence AGCGUGA from positions 2057-2063 relative to E. coli wildtype 23S rRNA. The 23S rRNA can include additional or alternative deletions, substitutions, insertions, or combination thereof. The compositions and methods can be used to make polypeptides and sequence defined polymers.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: December 21, 2021
    Assignee: YALE UNIVERSITY
    Inventors: Alanna Schepartz Shrader, Wesley E. Robertson, Clarissa Melo Czekster
  • Patent number: 11174489
    Abstract: The present invention relates to a yeast cell, in particular a recombinant yeast cell, the cell lacking enzymatic activity needed for the NADH-dependent glycerol synthesis or the cell having a reduced enzymatic activity with respect to the NADH-dependent glycerol synthesis compared to its corresponding wild-type yeast cell, the cell comprising one or more heterologous nucleic acid sequences encoding an NAD+-dependent acetylating acetaldehyde dehydrogenase (EC 1.2.1.10) activity. The invention further relates to the use of a cell according to the invention in the preparation of ethanol.
    Type: Grant
    Filed: February 15, 2021
    Date of Patent: November 16, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: Jacobus Thomas Pronk, Antonius Jeroen Adriaan Van Maris, Victor Gabriel Guadalupe Medina
  • Patent number: 11174499
    Abstract: The present invention relates to enzyme compositions and processes of producing and using the compositions for the saccharification of lignocellulosic material.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: November 16, 2021
    Assignee: Novozymes A/S
    Inventors: Jeffrey Shasky, Debbie Yaver, Donna Moyer
  • Patent number: 11162115
    Abstract: Systems, networks, methods, compositions and recombinant hosts for biosynthesizing hydrocarbons from a feedstock, such as gas, are provided.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: November 2, 2021
    Assignee: INV Nylon Chemicals Americas, LLC
    Inventors: Alexander Brett Foster, Leonard Keith Pattenden, Jonathan David Rand, Ana Teresa dos Santos Brito Mendes Roberts, Andrew Shaw, Mark Paul Taylor
  • Patent number: 11155804
    Abstract: Composition comprising purified recombinant selenoproteins, such an antibodies and enzymes, are provided. Method of producing such recombinant polypeptides and bacterial strains for the same are likewise provided.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: October 26, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Andrew D. Ellington, Ross Thyer
  • Patent number: 11154064
    Abstract: The present invention relates to a composition comprising a) recombinant exosporium-producing Bacillus cells that express a fusion protein comprising: (i) at least one plant growth stimulating protein or peptide and (ii) a targeting sequence that localizes the fusion protein to the exosporium of the Bacillus cells; and b) at least one further biological control agent selected from particular microorganisms disclosed herein and/or a mutant of a specific strain of a microorganism disclosed herein having all identifying characteristics of the respective strain, and/or at least one metabolite produced by the respective strain, and/or at least one metabolite produced by the respective strain that exhibits activity against insects, mites, nematodes and/or phytopathogens in a synergistically effective amount. Furthermore, the present invention relates to the use of this composition as well as a method for enhancing plant growth, promoting plant health, and/or reducing overall damage of plants and plant parts.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: October 26, 2021
    Assignees: Bayer CropScience LP, Spogen Biotech Inc.
    Inventors: Damian Curtis, Brian Thompson
  • Patent number: 11155799
    Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: October 26, 2021
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Chad Euler
  • Patent number: 11149092
    Abstract: Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over 5 half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 10 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: October 19, 2021
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Douglas S. Conklin, Cheryl Eifert, Antonis Kourtidis, Xianhui Wang, Leila Kokabee
  • Patent number: 11142749
    Abstract: The present invention is related to a trehalose phosphorylase comprising an amino acid sequence, wherein the amino acid sequence of the trehalose phosphorylase is at least 80% identical to and/or at least 80% homologous to an amino acid sequence of SEQ ID NO: 1, wherein the amino acid sequence of the trehalose phosphorylase comprises an amino acid substitution at one or more amino acid positions, wherein the one or more amino acid positions is/are selected from the group consisting of amino acid positions of SEQ ID NO: 1 712, 383, 10, 114, 118, 192, 197, 220, 225, 304, 306, 318, 323, 339, 349, 357, 459, 476, 481, 484, 487, 488, 506, 511, 526, 530, 532, 533, 537, 550, 556, 564, 590, 649, 667, 703 and 705.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: October 12, 2021
    Assignees: NEW MATTERHORN, LLC, c-LEcta GmbH
    Inventors: Birgit Brucher, Andreas Vogel
  • Patent number: 11142777
    Abstract: The present invention relates to a method for preparing a mutant strain having high producibility of phytoene and a mutant strain prepared thereby. More particularly, a Deinococcus radiodurans mutant strain, prepared by the method of the present invention, having high producibility of phytoene, does not retain an artificial antibiotic-resistant gene, although constructed by introducing a metabolism engineering method, and has high producibility of phytoene. Thus, the mutant strain prepared according to the method can find useful applications in the mass production of phytoene.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 12, 2021
    Assignee: University of Seoul Industry Cooperation Foundation
    Inventors: Yong Jun Choi, Sun Wook Jeong, Jua Kim, Eunkyung Hong, Kwang Jin Cho
  • Patent number: 11136604
    Abstract: The present invention relates to a method for producing chiral ?-nitro alcohol compounds. The invention relates in particular to an (R)-selective cupin-nitroaldolase, which enantioselectively can catalyze the Henry reaction, wherein an aldehyde or ketone compound is converted to the corresponding ?-nitro alcohol compound in the presence of a nitroalkane compound and a cupin-nitroaldolase.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: October 5, 2021
    Assignee: Patheon Austria GMBH & CO KG
    Inventors: Kerstin Steiner, Mandana Gruber, Romana Wiedner, Helmut Schwab
  • Patent number: 11136571
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: October 5, 2021
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Patent number: 11136601
    Abstract: The present disclosure relates to a genetically modified microbial cell that includes a genetic modification resulting in the expression of a vanillate demethylase, where the microbial cell is capable of metabolizing at least one S-lignin decomposition molecule including at least one of syringate and/or 3-O-methyl gallate, and the genetically modified microbial cell is capable of producing gallate. In some embodiments of the present disclosure, the vanillate demethylase may include VanAB.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: October 5, 2021
    Assignee: Alliance for Sustainable Energy, LLC
    Inventors: Gregg Tyler Beckham, Christopher W. Johnson, Sandra Fabienne Notonier
  • Patent number: 11130947
    Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: September 28, 2021
    Assignee: Codexis, Inc.
    Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
  • Patent number: 11111484
    Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: September 7, 2021
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Chad Euler
  • Patent number: 11104926
    Abstract: Provided are N,N?-diacyl rhodamine compounds, which may be converted to rhodamine by porcine liver esterase (PLE) to produce a fluorescence signal. These compounds may be used, for example, as substrates in enzymatic assays or as labels in cellular imaging.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: August 31, 2021
    Assignees: Vanderbilt University, Meharry Medical College
    Inventors: Gary A. Sulikowski, Kristopher K. Abney, Susan J. Ramos-Hunter, Ian M. Romaine, Charles David Weaver
  • Patent number: 11091787
    Abstract: Methods for recombinant and enzymatic production of mogroside compounds and compositions containing mogroside compounds are provided by this invention.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: August 17, 2021
    Assignee: EVOLVA SA
    Inventors: Jens Houghton-Larsen, Katarzyna Krzystanek, Angelika Semmler, Iver Klavs Riishede Hansen, Soren Damkiaer, Yaoquan Liu, Jorgen Hansen, Sathish Kumar, Muthuswamy Panchapagesa Murali, Nina Nicoline Rasmussen
  • Patent number: 11091749
    Abstract: Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: August 17, 2021
    Assignees: TRUSTEES OF DARTMOUTH COLLEGE, STEALTH BIOLOGICS, LLC
    Inventors: Karl E. Griswold, Chris Bailey-Kellogg, Yoonjoo Choi, Kristina Blazanovic, Hongliang Zhao, Deeptak Verma
  • Patent number: 11078299
    Abstract: Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: August 3, 2021
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Jie Zhou, Ching-Fun Lau, Zhiwen Xu, Wing-Sze Lo, Kristi Helen Piehl, Leslie Ann Greene